Click on the session title to see the details
Bloomberg Intelligence moderator describes legislative stakeholders and current policy proposals. Panelists representing all sides of the debate and from a variety of industries discuss what reforms are needed and how they affect licensing.
Tamlin Bason, Legal Associate, Bloomberg Analyst
Chris Israel, Partner, American Continental Group
Diane K. Lettelleir, Senior Managing Counsel, J.C. Penney Corporation
Dr. Hans Sauer, PhD, JD, Associate General Counsel Intellectual Property, Biotechnology Industry Organization (BIO)
Ryan Triplette, Director of Government Relations for the Intel Corporation, Franklin Square Group
A panel composed of Vehicle OEMs, Tier I suppliers and US Government Regulators aimed at discussing the introduction of Autonomous Vehicles and how the interplay between the safety needs of the driving public us regulators responsible for making safe autonomous vehicles a reality and the vehicle OEM/Tier I supplier community work together. The role of all three groups in creating IP, work together toward cooperating with regulators to provide this new technology to the driving public. The Panel will review the emerging standards, IP sharing and licensing and managing the needs of the standardization and safety in a competitive marketplace.
John Carney, Director of Commercialization & Licensing, Delphi Automotive Systems, LLC.
Frank MacKenzie, Senior Intellectual Property Counsel, Mobility, Autonomous Vehicles, Safety, and Electronics, Ford Motor Company
Justin Pierce, Chair of Intellectual Property Division, Venable LLP
David Strickland, Counsel, Self-Driving Coalition for Safer Streets; Former Head, US National Highway Transportation Safety Administration
Change is the only constant. The anticipated unwinding of the Affordable Care Act promises to change the horizon for pharma and biotech. Our panelists will provide insight and predictions about the potential implications of the ACA replacement legislation.
We will explore:
Join us as we share our thoughts on these topics and more. You can find additional background information on this topic here.
Karthika Perumal, Associate, Bracewell LLP
John Murphy, Deputy General Counsel, Biotechnology Innovation Organization
Alexander Puutio, Communications & IT Section, UN Secretariat-Procurement Division
Timothy P. Ribelin, Healthcare Attorney, Husch Blackwell LLP
Jayson Slotnik, Principal and Founding Member, Health Policy Strategies, LLC
The Honorable Scott Kieff will review the state of intellectual property policy in the US and overseas, including a perspective on trade and competition issues and what this means for the economics of licensing.
Hon. F. Scott Kieff, Commissioner, United States International Trade Commission
The last decade has seen increases in life science partnerships between industry and academic research. Simultaneously, there is an historic and potential future declines in basic research funding at the federal level. This workshop will explore the potential for partnerships that support non-profit research, including priorities and interests of industry funders, the handling of IP rights, and successful structures for partnerships. The workshop will include discussion on the following topics:
Participants will learn current practices in large-scale industry-non-profit research partnerships, the benefits and conflicts inherent in them, and preferred methods for creating and sustaining these partnerships.
Michael Perham, Head of Technology Transfer, HHMI/Janelia Research Campus
Gillian Fenton, Senior Counsel, Vaccines Legal Operations, GSK
Dave Greenwald Ph.D., Director of Corporate Relations, Johns Hopkins
Thomas Marron, Pharmaceutical Strategy and Operations, Eli Lilly and Company
Michael Straightiff, Executive Director, UVA Licensing & Ventures Group, University of Virginia
The panel will focus on educating the audience on ITC Investigations. The presentation will provide a general overview of ITC litigation; identify key issues to consider when deciding on which venue to pursue; identify specific factors to consider when establishing necessary proofs; and discuss how current events at the ITC may impact future investigations. The following topics will be addressed during the panel/presentation:
Justin Lewis, Managing Director, Ocean Tomo, LLC
Marcia Chang, Managing Director, Intellectual Property Sales and Licensing, Hewlett Packard Enterprise
George Koomullil, Founder and CEO, Relecura Inc.
Eric Podlogar, Senior Program Manager, KtMINE
Lynne Weber, Managing Director, Duff & Phelps, LLC
Discussion on the current state of IP Judicial Policy, PTAB, District, CAFC and Supreme Court, how they are impacting licensing and IP in the US. Bloomberg will give a high level description of key Judicial impacts on damages, patentability, etc. and panelists will give their thoughts on how they viewed making policy from the bench and now how they see judicial policy impacting innovation, licensing, etc. from off the bench.
Matt Larson, Tech Litigation Analyst, Bloomberg
Honorable Faith Hochberg, United States District Judge (retired)
Scott Kamholz M.D., Ph.D., PTAB Trial Lawyer and Former Judge, Covington & Burling LLP
Deanna Tanner Okun (Former ITC Chair), Partner, Adduci Mastriani & Schaumberg LLP
An interactive discussion of the potential use of IP-related voluntary consensus standards to facilitate -- and in some situations even replace – traditional decision making processes in judicial, legislative, regulatory and transactional settings.
Ron Laurie, Managing Director, Inflexion Point Strategy LLC
Judge Paul R. Michel (Ret.), U.S. Court of Appeals for the Federal Circuit Court
Susan Munck, Chief Counsel for Intellectual Property, and Deputy Director of Office of Policy Planning, Federal Trade Commission
Phil Strassburger, General Counsel, Purdue Pharma
Michael Thompson, Director, Aerospace Product Group, SAE International
The FDA is responsible for regulating 25% of the US economy – its mission is to promote health. With respect to drugs, its principal functions are to decide which drugs must be prescribed (versus available over the counter) and to make sure that all new drugs can be labeled for safe use and are effective. Due to fear from public and Congressional ridicule, the FDA has strayed in its mission such that its principal goal is to protect health. In doing so, it has, in practice, changed the safety and effectiveness requirements such that larger and longer trials are needed to obtain approval. This has had a chilling effect on medical innovation, has driven up drug prices, and has resulted in the development of niche products at the expense of those that can treat tens of millions of Americans. Returning the FDA to its proper role of adjudicating safety and effectiveness is necessary for scientific advancements to be translated into medical innovations available to doctors and patients.
Dr. Joe Gulfo, MD, MBA, Author, Executive Director, Fairleigh Dickinson University
IP executives from AT&T, Microsoft, Qualcomm and Visa will share their IoT vision, as markets are gearing to leverage on the promise of 20 billion connected devices by 2020. The panel will discuss current trends and revenue opportunities in technologies that fuel the IoT ecosystem, including: connected devices, wireless connectivity, big data analytics and security, as well as the industry sectors that are poised to grow fastest among the IoT verticals such as: automotive, fintech, healthcare, etc. As the IoT spans across multiple technologies, this panel will also discuss the new business and licensing models needed for companies to succeed in creating products and services.
Efrat Kasznik, President, Foresight Valuation Group
Andy Forsberg, Intellectual Property and Patent Licensing, Microsoft
Dmitry Milikovsky, Vice President, Business Development, Qualcomm
Sankara Narayanan Ph.D., Vice President, Business Development, Relecura
Joseph Sommer, Vice President, AT&T Intellectual Property, Inc.
Dr. Jerry Wald, Senior Director, Intellectual Asset Protection and Program Management Services, Visa
We’ve all heard enough about cybersecurity to be scared out of our minds. As the internet of things takes hold, data—important, proprietary, personal data—is subject to attack and ransom as it passes through all types of devices on its way to the cloud. Whether involving life-critical medical devices or ordinary household appliances, how we license, transfer, and protect data is more important than ever before. If we fail, our personal data, our company’s data, our client’s data—not to mention the future of our business reputation and growth—are all at risk. But there is hope! Hear from a panel of experts representing government, industry, security, and legal sectors as they discuss the latest cybersecurity trends, new, sophisticated behavior-analytics tools that can prevent attacks before they occur, and practical steps victims can take to minimize the damage, stop the wrongdoers, and be responsible community members. Come afraid and leave with a changed mindset ready to tackle cybersecurity with confidence.
Jonathon Hance, Bracewell LLP
Beth Richards, National Security Agency (NSA) Senior Executive, Senior Lead for Cyber at the Laboratory for Analytic Sciences, NSA
Mark Schildkraut, Associate General Counsel, IP and Cybersecurity, Becton Dickinson
Shamoil Shipchandler, Regional Director, U.S. Securities and Exchange Commission
An industry leading panel on intellectual property and licensing issues associated Augmented Reality (AR) and Virtual Reality (VR) including the related devices, software, and designs. Projected to exceed $150B by 2020, AR/VR is not only a patent centric minefield, but it contains new media combining Hollywood with Madison Avenue, requiring an entirely unique approach to the associated intellectual property and licensing.
Stephen Kabakoff, Partner, Finnegan Henderson
Marty Bijman, Director, IP Products, TechInsights
Charles Huston, Partner, Solomar
Daria Killebrew, Vice President, Analysis Group
Annie Rogaski,Vice President and General Counsel, Avegant Corp.
Please join us for a panel discussion of key provisions to include in energy licensing agreements. The panel will discuss testing, reverse engineering, sub-contracting, and other issues that arise in energy licensing agreements. The panel will also discuss lessons learned from past licensing agreements and will discuss key language that a licensor and licensee can agree on to clarify the obligations of each party.
Nicoletta M. Kennedy, Associate, Kilpatrick Townsend & Stockton LLP
Peter Christensen, Manager, Technology Commercialization, Pacific Northwest National Laboratory
Ronald J. Schutz, Managing Partner-New York, Robins Kaplan LLP
Alex Tang, Licensing and Commercialization Manager, Gas Technology Institute
Numerous industries are seeing increased reliance on (and litigation regarding) non-patent assets, particularly trademarks. However, building brands involves more than merely obtaining trademark registrations. Hear from industry professionals on how to build brands and create value.
Laura Goldbard George, Partner, Stroock & Stroock & Lavan LLP
Doug Bania, Principal, Nevium IP Solutions
John Favreau, President, Little Lake Partners, LLC
Nicole Pope, Counsel, Talent and Licensing, Feld Entertainment (Ringling Bros, Monster Jam, Disney on Ice)
Boston is a hub for activity in the Life Science industry due to the presence of leading universities, major research hospitals, venture capital resources, global corporations and an ever-expanding network of start-ups. Because Boston is viewed as an innovation center, some have argued that companies must move to Boston to succeed in this industry. This workshop will involve a candid discussion with various industry players to assess the impact of geography on deal making activity.
Faith Charles, Partner, Thompson Hine LLP
Richard Bendis, President and CEO, BioHealth Innovation Inc
Ranch Kimball, Managing Director of CIC, Secretary of Economic Development
Arthur M. Pappas MBA, Chief Executive Officer and Managing Partner, Pappas Capital, LLC
Baiju R. Shah, Chief Executive Officer, BioMotiv
Dr. Carl Spana, PhD, Chief Executive Officer, Palatin Technologies Inc